Treating primary progressive aphasia and elucidating neurodegeneration in the language network using transcranial direct current stimulation
使用经颅直流电刺激治疗原发性进行性失语症并阐明语言网络中的神经退行性变
基本信息
- 批准号:10201511
- 负责人:
- 金额:$ 75.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-08-15 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdvanced DevelopmentAffectAge-associated memory impairmentAlzheimer&aposs DiseaseAlzheimer&aposs disease patientAnodesAnteriorAreaBehavioralBrainBrain regionClinicalClinical TrialsCross-Over StudiesDataDegenerative DisorderDiseaseDisease ProgressionDouble-Blind MethodFrontotemporal DementiaFunctional Magnetic Resonance ImagingFunctional disorderFutureGoalsGraphImageIndividualInjuryInterventionIntervention TrialInvestigationKnowledgeLanguageLanguage TherapyLeftLocationMeasuresMethodsModelingNatureNerve DegenerationNeurodegenerative DisordersNeuronal PlasticityParticipantPathway AnalysisPatientsPatternPerformancePersonsPrimary Progressive AphasiaProductionPropertyQuality of lifeRandomizedResearchRoleSemanticsSiteSpeechStatistical Data InterpretationStatistical ModelsStructureSyndromeSystemTechniquesTestingTherapeuticVariantWorkbehavioral responsecerebral atrophyclinical phenotypedensityeffective therapyfrontal lobefrontotemporal degenerationimprovedindexinginsightlanguage impairmentmeetingsmultimodal dataneurodegenerative dementianeuroimagingneuroregulationnoninvasive brain stimulationnovelpredicting responserelating to nervous systemresponsestatisticsstroke-induced aphasiatreatment effecttreatment trial
项目摘要
PROJECT SUMMARY/ABSTRACT
This revised application responds to PAR-18-175: “Pilot Clinical Trials for the Spectrum of Alzheimer's Disease
and Age-related Cognitive Decline.” Primary progressive aphasia (PPA), a debilitating condition of language
loss affecting many patients with frontotemporal dementia (FTD) and Alzheimer's disease (AD), currently lacks
effective treatments. Recent studies suggest that transcranial direct current stimulation (tDCS), a form of
noninvasive neuromodulation, may show promise as an intervention for PPA. However, these research efforts
are hampered because they do not address important questions about plasticity in the language system, and
because they do not fully utilize knowledge regarding the properties of the language network in PPA to guide
treatment. This proposal aims to further advance investigation into tDCS as a potential intervention in PPA and
to establish which components of the language network in PPA are most capable of tDCS-induced behaviorally
relevant plasticity. Our proposal seeks to determine whether neuromodulation therapies in persons with PPA
should aim to strengthen connections in the most degenerated regions of the language network or bolster
compensatory changes in more intact areas. We will address this knowledge gap by pursuing a randomized,
sham-controlled crossover study of high-density tDCS (HD-tDCS) focused over the anterior regions of the left
hemisphere language network in participants with two PPA variants that are characterized by decreased word
production but which feature different sites of maximal degeneration. This will allow for comparison of
stimulation in a region that is degenerated in some subjects but relatively spared in others. Stimulation will be
paired with a behavioral language therapy aimed at augmenting tDCS effects in the language system. Our first
aim will be to determine how this intervention differentially impacts language performance in subjects with the
two PPA variants. We will then use network graph statistical analyses of neuroimaging data to characterize
language networks. We will focus on hubs as centers of critical connectivity in networks, and we propose that
measuring changes in the ability of regions in the language network to function as hubs (indexed by hub
scores) may be a way to describe how neurodegeneration impacts language network functions in PPA. Thus,
the second aim of the proposal will explore differences in hub scores across the language network at baseline
in our two PPA subtype groups. The third aim of the proposal will extend this approach by examining
behaviorally relevant changes in hub scores induced by tDCS. The final aim of the project will integrate and
extend prior findings by developing a model that employs clinical phenotypes, patterns of brain atrophy, and
hub score data to predict which individuals are most likely to benefit from our stimulation approach. Taken
together, this project will advance a potential intervention for a devastating condition associated with
neurodegenerative diseases, elucidate network mechanisms of plasticity in these disorders, and develop a
potentially generalizable, network-informed approach for predicting response to therapeutic neuromodulation.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Roy H Hamilton其他文献
Disparities in Genetic Testing for Neurologic Disorders.
神经系统疾病基因检测的差异。
- DOI:
10.1212/wnl.0000000000209161 - 发表时间:
2024 - 期刊:
- 影响因子:9.9
- 作者:
A. Baldwin;Juliette Copeland;Meron Azage;Laynie Dratch;Kelsey Johnson;Rachel A Paul;Defne A. Amado;M. Baer;Andres Deik;Lauren B. Elman;Michael Guo;A. Hamedani;David J Irwin;Aaron Lasker;Jennifer Orthmann;Colin C. Quinn;T. Tropea;Steven S Scherer;Russell T Shinohara;Roy H Hamilton;Colin A Ellis - 通讯作者:
Colin A Ellis
Abstracts of Scientific Papers and Posters Presented at the Annual Meeting of the Association of Academic Physiatrists: New Orleans, Louisiana March 6 – 10, 2013
学术物理医师协会年会上发表的科学论文和海报摘要:路易斯安那州新奥尔良,2013 年 3 月 6 日至 10 日
- DOI:
- 发表时间:
2013 - 期刊:
- 影响因子:3
- 作者:
Steven A Mann;Dae Hyeon Kim;M. DiVita;Andrew G Reish;Michael Rhee;Roy H Hamilton;Preeti Sunderaraman;Kelli S Williams - 通讯作者:
Kelli S Williams
Roy H Hamilton的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Roy H Hamilton', 18)}}的其他基金
Phase II clinical trial of transcranial direct current stimulation in the treatment of primary progressive aphasia
经颅直流电刺激治疗原发性进行性失语症II期临床试验
- 批准号:
10522254 - 财政年份:2022
- 资助金额:
$ 75.5万 - 项目类别:
Phase II clinical trial of transcranial direct current stimulation in the treatment of primary progressive aphasia
经颅直流电刺激治疗原发性进行性失语症II期临床试验
- 批准号:
10705285 - 财政年份:2022
- 资助金额:
$ 75.5万 - 项目类别:
Treating primary progressive aphasia and elucidating neurodegeneration in the language network using transcranial direct current stimulation
使用经颅直流电刺激治疗原发性进行性失语症并阐明语言网络中的神经退行性变
- 批准号:
10450141 - 财政年份:2019
- 资助金额:
$ 75.5万 - 项目类别:
TMS as a Biomarker of Plasticity in Aphasia Recovery
TMS 作为失语症恢复可塑性的生物标志物
- 批准号:
8578928 - 财政年份:2013
- 资助金额:
$ 75.5万 - 项目类别:
TMS as a Biomarker of Plasticity in Aphasia Recovery
TMS 作为失语症恢复可塑性的生物标志物
- 批准号:
9097676 - 财政年份:2013
- 资助金额:
$ 75.5万 - 项目类别:
TMS as a Biomarker of Plasticity in Aphasia Recovery
TMS 作为失语症恢复可塑性的生物标志物
- 批准号:
8688215 - 财政年份:2013
- 资助金额:
$ 75.5万 - 项目类别:
TMS as a Biomarker of Plasticity in Aphasia Recovery
TMS 作为失语症恢复可塑性的生物标志物
- 批准号:
9304199 - 财政年份:2013
- 资助金额:
$ 75.5万 - 项目类别:
TMS to explore interhemispheric interactions and to treat aphasia and neglect
TMS 探索大脑半球间的相互作用并治疗失语症和忽视
- 批准号:
7531513 - 财政年份:2008
- 资助金额:
$ 75.5万 - 项目类别:
TMS to explore interhemispheric interactions and to treat aphasia and neglect
TMS 探索大脑半球间的相互作用并治疗失语症和忽视
- 批准号:
7620029 - 财政年份:2008
- 资助金额:
$ 75.5万 - 项目类别:
TMS to explore interhemispheric interactions and to treat aphasia and neglect
TMS 探索大脑半球间的相互作用并治疗失语症和忽视
- 批准号:
7806482 - 财政年份:2008
- 资助金额:
$ 75.5万 - 项目类别:
相似海外基金
ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
- 批准号:
10935820 - 财政年份:2023
- 资助金额:
$ 75.5万 - 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
- 批准号:
10932514 - 财政年份:2023
- 资助金额:
$ 75.5万 - 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
- 批准号:
10704845 - 财政年份:2023
- 资助金额:
$ 75.5万 - 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
- 批准号:
10709085 - 财政年份:2023
- 资助金额:
$ 75.5万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10409385 - 财政年份:2022
- 资助金额:
$ 75.5万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10710595 - 财政年份:2022
- 资助金额:
$ 75.5万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10630975 - 财政年份:2022
- 资助金额:
$ 75.5万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
- 批准号:
10710588 - 财政年份:2022
- 资助金额:
$ 75.5万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10788051 - 财政年份:2022
- 资助金额:
$ 75.5万 - 项目类别: